
CD46 - Wikipedia
CD46 complement regulatory protein also known as CD46 (cluster of differentiation 46) and Membrane Cofactor Protein is a protein which in humans is encoded by the CD46 gene. [5] …
CD46 Gene - GeneCards | MCP Protein | MCP Antibody
Mar 28, 2025 · CD46 (CD46 Molecule) is a Protein Coding gene. Diseases associated with CD46 include Hemolytic Uremic Syndrome, Atypical 2 and Genetic Atypical Hemolytic-Uremic …
Membrane cofactor protein (MCP; CD46): deficiency states and …
Membrane cofactor protein (MCP; CD46), a ubiquitously expressed complement regulatory protein, serves as a cofactor for serine protease factor I to cleave and inactivate C3b and C4b …
CD46 in innate and adaptive immunity: an update - PMC
CD46-mediated signals regulate innate and adaptive immune cell function. (a) CD46 modulates innate cell functions. CD46 cross-linking by natural and pathogenic ligands suppresses …
Structure of the Extracellular Portion of CD46 Provides Insights …
Sep 30, 2010 · The human membrane cofactor protein (MCP, CD46) is a central component of the innate immune system. CD46 protects autologous cells from complement attack by binding …
CD46: a complement regulator and pathogen receptor that ... - PubMed
CD46 not only protects cells from complement-mediated attack and facilitates infection by a large number of pathogens, but also exerts complex effects on cellular immune function.
Complement regulator CD46: genetic variants and disease …
Jun 10, 2015 · Membrane cofactor protein (MCP; CD46) is an ubiquitously expressed complement regulatory protein that protects host cells from injury by complement. This type-I …
CD46 - an overview | ScienceDirect Topics
CD46 is a widely expressed transmembrane protein that was initially identified as binding and inactivating C3b and C4b complement products. CD46 is also recognized by several human …
CD46: the 'multitasker' of complement proteins - PubMed
In particular, the complement regulator CD46 emerges as a key sensor of immune activation and a vital modulator of adaptive immunity. In this review, we summarize the current knowledge of …
Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune …
The starting dose of FOR46 was 0.1 mg/kg given intravenously every 3 weeks. The primary objective was to determine the maximally tolerated dose (MTD). Whole-blood mass cytometry …